论文部分内容阅读
目的:对急性支气管肺炎采用氨溴特罗口服液对症治疗的临床效果进行观察、总结和分析。方法:以2013年7月至2015年8月在该院接受治疗的140例支气管肺炎患儿为研究对象,随机分为观察组和对照组,各70例,其中对照组患儿采用常规抗感染治疗,而观察组患者在常规抗感染治疗的基础上采用氨溴特罗口服液进行对症治疗。对比两组患儿的临床效果。结果:观察组患儿的症状改善速度明显优于对照组,住院天数少于对照组,且差异具有统计学意义(P<0.05),此外观察组患儿治疗的总有效率94.3%明显高于对照组的总有效率82.9%,差异具有统计学意义(P<0.05)。结论:氨溴特罗口服液对症治疗急性支气管肺炎的临床效果较好,可以在临床上广泛应用。
OBJECTIVE: To observe, summarize and analyze the clinical effect of using ambroxol oral solution for acute bronchopneumonia. Methods: A total of 140 children with bronchial pneumonia treated in our hospital from July 2013 to August 2015 were randomly divided into observation group and control group, with 70 cases in each group. The control group received routine anti-infection The patients in observation group were given symptomatic treatment with ambroxol oral solution on the basis of conventional anti-infective therapy. Compare the clinical effect of two groups of children. Results: The symptom improvement rate in observation group was significantly better than that in control group, the days of hospitalization were less than those in control group, and the difference was statistically significant (P <0.05). In addition, the total effective rate in treatment group was 94.3% The total effective rate of the control group was 82.9%, the difference was statistically significant (P <0.05). Conclusion: Ambroxol oral solution has a good clinical effect on symptomatic treatment of acute bronchopneumonia and can be widely used clinically.